Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,288)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04809233 | Expanded Access to Tipifarnib(Kuraoncology) | available | — | — | Kura Oncology, Inc.INDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT05776160 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT05776134 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT05346835 | Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma | available | — | — | Janssen Scientific Affairs, LLCINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT05619367 | A Compassionate Use (CU) Program of Odronextamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Dec 23, 2025 | clinicaltrials |
| NCT04771078 | Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release | available | — | — | CelgeneINDUSTRY | 0 | Dec 12, 2025 | clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT03763370 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma | available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Oct 15, 2024 | clinicaltrials |
| NCT01250808 | Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy | available | — | — | Peking UniversityOTHER | 1 | Dec 1, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jun 29, 2026source: clinicaltrials